Understanding long-term protection of human papillomavirus vaccination against cervical carcinoma: Cancer registry-based follow-up

International Journal of Cancer

Volumn 132, Issue 12, 2013, Pages 2833-2838

  Rana, Muhammad Mohsin ^a   Huhtala, Heini ^a   Apter, Dan ^b   Eriksson, Tiina ^a   Luostarinen, Tapio ^c   Natunen, Kari ^a   Paavonen, Jorma ^d   Pukkala, Eero ^c   Lehtinen, Matti ^a  

^a TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^b Family Federation of Finland ^*  (Finland)

^c FINNISH CANCER REGISTRY   (Finland)

^d UNIVERSITY OF HELSINKI   (Finland)

Author keywords

Cancer Registry; cervical neoplasia; follow up; human papillomavirus; vaccination

Indexed keywords

PLACEBO; WART VIRUS VACCINE;

ADOLESCENT; ADULT; ARTICLE; CANCER IMMUNIZATION; CANCER INCIDENCE; CANCER PREVENTION; CANCER REGISTRY; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE SURVEILLANCE; DRUG EFFECT; FEMALE; FINLAND; FOLLOW UP; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 11; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 6; MAJOR CLINICAL STUDY; PAPILLOMAVIRUS INFECTION; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; UTERINE CERVIX CARCINOMA IN SITU;

ADOLESCENT; ADULT; CANCER VACCINES; FEMALE; FINLAND; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS VACCINES; POPULATION SURVEILLANCE; REGISTRIES; UTERINE CERVICAL NEOPLASMS; VACCINATION; YOUNG ADULT;

EID: 84876107900     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.27971     Document Type: Article

References (29)

1. Ferlay J, Shin HR, Bray F, et al. GLOBOCAN 2008 v1.2, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10 [Internet]. Lyon, France: International Agency for Research on Cancer; 2010. Available from: http://globocan.iarc.fr, accessed on 31/12/2011.
2. Muñoz N, Bosch FX, de Sanjosé S, et al.; International Agency for Research on Cancer Multicenter Cervical Cancer Study Group. Epidemiological classification of human papillomavirus types associated with cervical cancer. NEJM 2003; 348: 518-27.
3. Smith JS, Lindsay L, Hoots B, et al. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int J Cancer 2007; 121: 621-32.
4. Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999; 189: 12-19.
5. Bosch FX, Lorincz A, Muñoz N, et al. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 2002; 55: 244-65.
6. FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007; 356: 1915-27.
7. The FUTURE I/II Study Group. Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial. BMJ 2010; 340: c3493.
8. Paavonen J, Lehtinen M,. Introducing human papillomavirus vaccines-questions remain. Ann Med 2008; 40: 162-6.
9. Muñoz N, Kjaer SK, Sigurdsson K, et al. Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women. J Natl Cancer Inst 2010; 102: 325-39.
10. Carreon JD, Sherman ME, Guillén D, et al. CIN2 is a much less reproducible and less valid diagnosis than CIN3: results from a histological review of population-based cervical samples. Int J Gynecol Pathol 2007; 26: 441-6.
11. Castle PE, Schiffman M, Wheeler CM, et al. Evidence for frequent regression of cervical intraepithelial neoplasia-grade 2. Obstet Gynecol 2009; 113: 18-25.
12. Lehtinen M, Herrero R, Mayaud P, et al. Studies to assess the long-term efficacy and effectiveness of HPV vaccination in developed and developing countries. Vaccine 2006; 24S: 233-41.
13. Lehtinen M, Idänpään-Heikkilä I, Lunnas T, et al. Population-based enrolment of adolescents in a long-term follow-up trial of human papillomavirus vaccine efficacy. Int J STD AIDS 2006; 17: 237-46.
14. Lehtinen M, Apter D, Dubin G, et al. Enrolment of 22,000 adolescent women to cancer registry follow-up for long-term human papillomavirus vaccine efficacy: guarding against guessing. Int J STD AIDS 2006; 17: 517-21.
15. Paavonen J, Jenkins D, Bosch FX, et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind randomised controlled trial. Lancet 2007; 369: 2161-70.
16. Lehtinen M, Kaasila M, Pasanen K, et al. Seroprevalence atlas of infections with oncogenic and nononcogenic human papillomaviruses in Finland in the 1980s and 1990s. Int J Cancer 2006; 119: 2612-19.
17. Castro FA, Haimila K, Pasanen K, et al. Geographic distribution of cervical cancer associated HLA antigens and cervical cancer incidence in Finland. Int J STD AIDS 2007; 18: 672-9.
18. Kaasila M, Koskela P, Kirnbauer R, et al. Population dynamics of serologically identified coinfections with human papillomavirus types 11, 16, 18 and 31 in fertile-aged Finnish women. Int J Cancer 2009; 125: 2166-72.
19. Teppo L, Pukkala E, Lehtonen M,. Data quality and quality control of a population-based cancer registry: experience in Finland. Acta Oncol 1994; 33: 365-9.
20. Finnish Cancer Registry. http://www.cancer.fi. Accessed on October 1, 2012.
21. Nieminen PJ, Anttila A, Heikkilä E, et al. Kohdunkaulan, emättimen ja ulkosynnytinten solumuutokset-diagnostiikka, hoito ja seuranta: Käypä hoito -suositus. Duodecim 2010; 126: 1965-6.
22. Orenstein WA, Bernier RH, Dondero TJ, et al. Field evaluation of vaccine efficacy. Bull World Health Organ 1985; 63: 1055-68.
23. Halloran ME, Structhiner CJ, Longini IM, Jr., Study designs for evaluating different efficacy and effectiveness aspects of vaccines. Am J Epidemiol 1997; 146: 789-803.
24. Chan Ivan SF, Bohidar NR,. Exact power and sample size for vaccine efficacy studies. Commun Stat Theory Methods 1998; 27: 1305-22.
25. O'Neill RT,. On sample sizes to estimate the protective efficacy of a vaccine. Stat Med 1988; 7: 1279-88.
26. Lemeshow S, Hosmer DW, Jr, Klar J, et al. Adequacy of sample size in health studies. Chichester: WHO, Wiley, 1990.
27. Altman DG, Machin D, Bryant TN, et al., eds. Statistics with confidence, 2nd edn. Bristol: BMJ Books; 2000.
28. Sigstad E, Lie AK, Luostarinen T, et al. A prospective study of the relationship between prediagnostic human papillomavirus seropositivity and HPV DNA in subsequent cervical carcinomas. Br J Cancer 2002; 87: 175-80.
29. Arnheim Dahlström L, Andersson K, Luostarinen T, et al. Prospective seroepidemiologic study of human papillomavirus and other risk factors in cervical cancer. Cancer Epidemiol Biomarkers Prev 2011; 12: 2541-50.